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Abstract
Background: The discovery that nerve growth factor (NGF) metabolism is altered in
Down syndrome (DS) and Alzheimer’s disease (AD) brains offered a framework for the
identification of novel biomarkers signalling NGF deregulation in AD pathology.
Methods:We examined levels of NGF pathway proteins (proNGF, neuroserpin, tissue
plasminogen activator [tPA], and metalloproteases [MMP]) in matched cerebrospinal
fluid (CSF)/plasma samples from AD-symptomatic (DSAD) and AD-asymptomatic
(aDS) individuals with DS, as well as controls (HC).
Results: ProNGF and MMP-3 were elevated while tPA was decreased in plasma from
individuals with DS. CSF from individuals with DS showed elevated proNGF, neuroser-
pin, MMP-3, and MMP-9. ProNGF and MMP-9 in CSF differentiated DSAD from aDS
(area under the curve = 0.86, 0.87). NGF pathway markers associated with CSF amy-
loid beta and tau and differed by sex.
Discussion: Brain NGFmetabolism changes can be monitored in plasma and CSF, sup-
porting relevance in AD pathology. These markers could assist staging, subtyping, or
precisionmedicine for AD in DS.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
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1 INTRODUCTION
Individuals with Down syndrome (DS) represent the largest geneti-
cally determined population at risk for Alzheimer’s disease (AD).1–6
A critical factor associated with cognitive decline in AD, both in the
general population and in DS, is the degeneration of the cortical fore-
brain cholinergic system.5,7–14 Cholinergic neurodegeneration in these
disorders has been linked to dysregulation of the nerve growth fac-
tor (NGF) metabolic pathway.15–19 This pathway controls the matu-
ration and degradation of the neurotrophin NGF, on which forebrain
cholinergic neurons depend.20 In this pathway, the tissue plasmino-
gen activator (tPA)/plasminogen system is responsible for the matu-
ration of NGF from its precursor, proNGF, a process that is inhibited
by neuroserpin.20,21 The extracellular degradation of mature NGF is
accomplishedprimarily bymatrixmetalloproteinase (MMP)-9,20 which
can be activated byMMP-322 and is inhibited by tissue inhibitormetal-
loproteinase (TIMP)-1.23
ProNGF levels have been found to be elevated in AD brains with
advanced pathology.24 The NGF metabolic pathway has likewise been
found to be dysregulated in mild cognitive impairment (MCI), AD, and
apparently healthy individuals with elevated brain amyloid17,25,26 as
well as in the brains of people with DS and AD dementia.15 NGF dys-
regulation in the early phases of AD correlates to cholinergic dysfunc-
tion and cognitive decline,26 and the ability tomonitor this dysfunction
through biomarkers would have high potential utility in research and
clinical contexts.27,28
Correspondingly, an analysis of NGF metabolic pathway markers
in plasma samples from people with DS has previously revealed that
the levels of NGF metabolism-associated markers, including proNGF,
MMP-1, MMP-3, and MMP-9 were elevated in individuals with DS,
with and without the cognitive symptoms of AD.16 Critically, it was
demonstrated that longitudinal within-subjects increases in proNGF
over 1 year correlated with cognitive decline over the subsequent 2
years.16
While plasma is themost accessible body fluid for themeasurement
of biomarkers, cerebrospinal fluid (CSF) can more faithfully reflect
changes in the brain, as it is in direct contact with the extracellular
central nervous system (CNS) milieu. Therefore, in this study, we ana-
lyzed a unique set of matched plasma and CSF samples from adults
with DS with and without AD dementia, as well as from healthy, non-
DS controls. The use of matched samples offers a unique opportunity
to directly compare the performance of markers in the two most com-
monly analyzed biofluids as well as to assess their correspondence,
which could support the ability of plasma markers to reflect changes
in the CNS milieu. The present study confirms and elaborates upon
our previous findings of dysregulation of NGF metabolism-associated
proteins16,29 in a new, independent clinical cohort of individuals with
DS, and extends it by showing that such changes also exist in CSF
and in fact better reflect the NGF metabolic changes observed in the
brain. We also demonstrate that CSF proNGF and MMP-9 can effec-
tively differentiate AD-symptomatic individuals with DS from those
whowere asymptomatic, and that proteins related toNGFmetabolism
correlate to core biomarkers of AD, especially when measured in
CSF.
2 MATERIALS AND METHODS
2.1 Study cases
Adults with DS aged 18 years and older were recruited by the
Alzheimer-Down Unit of the Fundació Catalana Síndrome de Down
and the Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, total-
ing 37 cases who assented to blood and CSF extraction. Participants or
their legal representative gave written informed consent, as approved
by the ethics committee of Hospital Sant Pau following the standards
for medical research in humans recommended by the Declaration of
Helsinki and reported to theMinistry of Justice according to the Span-
ish law for research in people with intellectual disabilities. Subjects
were required to understand and accept the study procedures to give
informed consent. Genetic screening of trisomy 21 aneuploidy was
done as previously described, confirming full trisomy of chromosome
21 in 95% of participants.30
Participants received a neurological and neuropsychological
examination which included the Cambridge Cognitive Examination
(CAMCOG) and Cambridge Examination for Mental Disorders of
the Elderly-Down Syndrome (CAMDEX-DS) batteries, as previously
described.30 Behavioral measures were assessed with the Neuropsy-
chiatric Inventory.31 We stratified the level of intellectual disability
according to the Diagnostic and Statistical Manual of Mental Disor-
ders, Fifth Edition as mild, moderate, or severe or profound (which
were grouped together), based on the individuals’ best-ever level of
functioning as determined from carers’ reports. Participants were
classified as asymptomatic, without AD-related cognitive impairment
(aDS; n = 14), prodromal AD (n = 10), or AD dementia (n = 12) in a
consensus meeting between the neurologist and the neuropsychol-
ogists who assessed them blind to the biomarker data, as previously
described.30 One participant was classified as ’uncertain’ and excluded
from analysis. Pilot studies with these samples indicated no significant
differences in NGF biomarkers between the prodromal AD and AD
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dementia groups, and these were therefore grouped together as a
symptomatic AD group (referred to as DSAD) to conserve statistical
power.
Control subjects were healthy volunteers of both sexes (age range
20 to 60 years, n = 16) recruited from the SPIN cohort (Sant Pau
Initiative on Neurodegeneration).32 Volunteers had no neurologi-
cal deficits, a Clinical Dementia Rating (CDR) total score of zero,
and with normal levels in core AD CSF biomarkers (amyloid beta
[Aβ]42/Aβ40, total tau [t-tau] and phosphorylated tau [p-tau]) assessed
by Lumipulse (LUMIPULSE G600II automated platform, Fujirebio).33
For both cohorts (DS and controls), the period of recruitment was
between November 2013 and November 2015. Apolipoprotein E
(APOE) allele genotyping was done as previously described.34 Table 1
illustrates the demographics of the populations included in this
study.
2.2 Plasma collection
Plasma samples were collected and processed following international
protocols35 and established procedures at the Sant Pau Memory Unit
laboratory.30 Briefly, fasting venous blood was collected in lavender
EDTA-K2 BD vacutainer tubes and centrifuged at 2000 g for 10 min-
utes at 4◦C for plasma separation. Plasma samples were separated
in aliquots of 100, 250, and 500 μl with protease inhibitors (cOm-
plete,Mini Protease Inhibitors, Roche) and stored at –80◦C. Theywere
shipped on dry ice to McGill University and upon arrival were immedi-
ately stored at –80◦ until analysis. Sampleswere analyzedwithin12-18
months after collection. Freeze-thaw cycles wereminimized to three.
2.3 CSF collection via lumbar puncture
A plasma-paired CSF sample of every subject was obtained at the
time of blood collection. Lumbar puncture was performed by a spe-
RESEARCH INCONTEXT
1. Systematic review: We used PubMed to review stud-
ies pertaining to the plasma/cerebrospinal fluid (CSF)
biomarkers of central nervous system cholinergic deficit
and nerve growth factor (NGF) metabolism in Down
syndrome (DS). Basal forebrain cholinergic degeneration
and NGF metabolic deficits have been demonstrated in
DS brains. One study in 2016 showed an altered NGF
metabolic signature in DS plasma. There were no reports
in CSF.
2. Interpretation: Our findings indicate that NGF metabolic
alterations can be monitored in plasma and CSF in DS,
though CSF more closely reflects the changes observed
in brain. Two CSF markers (proNGF 50 KDa andMMP-9)
distinguishedAD-symptomatic individuals from the over-
all DS population. These markers could have relevance
for diagnosis, staging, subtyping, or precisionmedicine for
AD in DS.
3. Future directions: NGF metabolic signatures should also
be tested in biofluids from familial and sporadic AD,
both pre- and post-symptomatically. In DS, associa-
tions with cognitive decline, basal forebrain imaging,
and cholinergic positron emission tomography would be
revealing.
cialized neurologist at the Sant PauHospital (Barcelona, Spain), follow-
ing international consensus recommendations for CSF collection.36–39
The procedure was performed either in sitting or lying position, using
a pen-point atraumatic spinal needle (Whitacre-22G). CSF was col-
lected by free-flow/dripping in 10 mL polypropylene tubes (Sarstedt,
Ref# 62.610.018) and processed within 2 hours after acquisition and
aliquoted as previously described.33 The Memory Unit laboratory at
TABLE 1 Characteristics of the study cohort
HC aDS DSAD Test for difference
Number of cases 16 14 22
Age (± SEM) 52.8± 1.1 39.9± 2.9 52.9± 2.9 1way ANOVA, P< .001 (aDS
lower thanHC/DSAD)
Proportion female 0.44 0.50 0.50 Chi-square test of
independence,Χ2 > 0.05



















Notes: Individuals with aDS were younger than those with DSAD as well as non-trisomic controls. Sex and APOE allele balance were equivalent between all
groups. Underlying intellectual disability was equivalent between the aDS andDSAD groups.
Abbreviations: aDS, Alzheimer’s disease asymptomatic; ANOVA, analysis of variance; APOE, apolipoprotein E; DSAD, Down syndrome Alzheimer’s disease;
HC, healthy control; SEM, standard error of themean.
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the SantPauHospital participates in theAlzheimer’sAssociation exter-
nal quality control program for CSF biomarkers. CSF aliquots were
stored at –80◦C, shipped on dry ice to McGill University, and upon
arrival were immediately stored at –80◦C. Samples were analyzed
within 12-18 months after collection. Freeze-thaw cycles were mini-
mized to three.
2.4 Analysis of proNGF and neuroserpin
Analysis of proNGF and neuroserpin in plasma and CSF was done
by Western blotting, following established procedures at the McGill
laboratory.15–17,26,40 Briefly, plasma samples (diluted in phosphate
buffered saline) and undiluted CSFwere incubated in standard loading
buffer under reducing conditions (5% β-mercaptoethanol), and loaded
on 10% to 12% SDS-polyacrylamide gels and semi-dry transferred to
nitrocellulose membranes (BioRad, USA) for 60 minutes at 220 mA.
Membranes were blocked for 1 hour in 5% bovine serum albumin
(Sigma, USA) in tris-buffered saline-polysorbate 20 0.1% (TBS-T) and
incubated with anti-proNGF antibodies (Alomone Labs, Israel; at
1:2000) or anti-neuroserpin antibodies (kindly provided by Dr. Daniel
Lawrence, University of Michigan, USA; at 1:5000), overnight at 4◦C
in blocking solution. Anti-mouse or anti-rabbit peroxidase-conjugated
secondary antibodies (Jackson Immunoresearch, USA) were applied
for 1 hour at room temperature in blocking solution. Immunoblots
were developed with the Western Lightning Plus-ECL substrate
(PerkinElmer Inc, USA) on Hyblot CL films (Denville, Canada). Films
were digitized and the relative levels of proNGF (27 kDa and 50 kDa
bands) and neuroserpin (45 kDa band) were quantified with the
Gel-Pro Analyzer (Media Cybernetics, Inc., USA) and the TotalLab
CLIQS Software (TotalLab, UK). The densitometry of each sample
was normalized to that of an internal control, a plasma or CSF
sample that was loaded in all gels, and each value was expressed
as relative fold-change with respect to the average of the control
group. ProNGF and neuroserpin determinations were done in three
independent experiments by independent investigators blinded to
the clinical diagnosis of the cases. The values were averaged for
analysis. Quantifiability across physiologically relevant concentra-
tions/integrated optical density (IOD) values was established by
reconstitution experiments in which plasma/CSF was spiked with 2, 5,
10, or 20 ng of human recombinant proNGF protein (Alomone Labs,
Israel), and subsequently analyzed by Western blotting as described
above. As shown in Figure S1 in the Supplementary Files, responses
were linear across the range of 2 to 10 ng and showed a minimal
(15%) increase in IOD response in the 20 ng sample in plasma (see
Figure S1A and S1B). In CSF, all responses were linear (see Figure
S1C and S1D). Spike-response patterns did not differ in plasma or CSF
samples from controls (HC) versus individuals with DS (Figure S1A
vs S1B; S1C vs S1D). All experimental values obtained by Western
blotting fell within the linear range. The identity of each proNGF band
was established and confirmed in previous reports by a variety of
methods.15–17,26,40
2.5 Analysis of metallo-proteases
The levels (pg/mL) of MMP-1, MMP-3, and MMP-9 in diluted plasma
and CSF samples (1:10) were measured with a Multi-Spot MMP 3-
Plex Ultra-Sensitive kit (MesoScale Discovery, USA), following manu-
facturer’s instructions. Electrochemiluminiscent signals were read in
a SECTOR Imager 2400 (MesoScale Discovery, USA) and the con-
centration of each metalloprotease was determined from a standard
curve generated by the MSD Discovery Workbench software v. 4.0.
(MesoScale Discovery, USA). Samples that fell below the detection
threshold were not considered for analysis. Each sample was analyzed
in three independent experiments from separate aliquots by indepen-
dent investigators. The average values of all assays were used for anal-
ysis.
2.6 Analysis of tPA
The plasma and CSF levels of tPA were measured with a Human Tis-
sueTypePlasminogenActivatorELISA (enzyme-linked immunosorbent
assay) kit (TPA; ab108914, Abcam, USA). tPA levels were measured in
undiluted plasma and in diluted CSF samples (1:2), following the pro-
tocol detailed by the manufacturer. For the calibration curve used in
the analysis of plasma samples, human tPA standards were diluted in
tPA-depleted plasma, provided by the manufacturer. The assay range
for tPA quantification was 0.02 to 10 ng/mL.
2.7 Statistical analysis
Unless otherwise stated, data analyses were done with the soft-
ware GraphPad Prism v7.00a (GraphPad, USA). Significance was set at
P < .05. Normality of data distribution was tested with the D’Agostino
and Pearson omnibus K2 test. If data normality was violated, analysis
was done with non-parametric statistics. Outliers were removed at a
threshold of 3x the standard error of the mean. Differential expres-
sion of NGF metabolism-related proteins across clinical classifications
was analyzed with a one-way analysis of variance (ANOVA) and Bon-
ferroni post hoc tests, if normally distributed, or Kruskal-Wallis tests
and Dunn’s post hoc correction if non-normal. The specificity of the
biomarkers to DSAD was assessed by the area under a receiver oper-
ator characteristic (ROC) curve comparing the DSAD and aDS pop-
ulations. Assessments of the effect of sex on biomarker expression
was performed with a two-way ANOVA or Friedman non-parametric
test, in the case of non-normally distributed data, looking for main
effects of sex and sex-by-diagnosis interactions. Note that expression
levels of each protein are not considered independent of one another
and their relationships are described in Table S1 in the Supplemen-
tary Files. The relationships between theCSF and plasma levels of each
NGFmetabolism-relatedprotein, aswell as their associationswith core
CSF biomarkers of AD, displayed evidence of heteroskedasticity and
were therefore assessed using the MM-estimation method of Crout
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et al.,41 which is robust to outliers and heterogeneity of variance. This
analysis was performed using R (R Project for Statistical Computing,
https://www.R-project.org).
3 RESULTS
Table 1 summarizes the demographic information of the study partici-
pants. The aDS group was younger than DSAD and control individuals,
although the age difference was not significant. There were no differ-
ences in the proportion of females or proportion of APOE ε4 carriers
between clinical groups. The DSAD group had a higher proportion of
individuals with severe intellectual disability than the aDS group.
3.1 Increased proNGF levels in plasma and CSF
from individuals with aDS and DSAD
As there are no existing ELISAs that can differentiate different forms
of proNGF, we assessed them usingWestern blotting. This allowed the
detection of a 27 kDa proNGF form corresponding to unprocessed
proNGF,42–44 and another one of higher molecular weight at 50 kDa,
suggested to represent glycosylated proNGF42–45 and/or complexes of
proNGFwithmacromolecules such as α2-macroglobulin.46
Analysis of the 27 kDa form of proNGF revealed a significant 40%
increase in plasma in aDS as well as in DSAD individuals compared to
non-trisomic controls (Figure 1A, P < .05). An 80% upregulation of the
27 kDa proNGF band was observed in paired CSF samples (from the
same individuals) in both the aDS and DSAD groups compared to non-
trisomic controls (Figure 1B, P < .01 and P < .001). CSF and plasma
levels of proNGF 27 kDa significantly correlated (P < .01, r2= 0.12,
Table S1).
The 50 kDa form of proNGF was also upregulated in plasma from
people with aDS and DSAD compared to controls (Figure 1C, P < .05),
similarly to the 27 kDa form. CSF analysis further revealed higher lev-
els of 50 kDa proNGF in the aDS and DSAD groups compared to non-
trisomic controls, and further elevated levels in the DSAD group com-
pared to the aDS group (Figure 1D, P < .0001 and P < .01). Plasma and
CSF levels of proNGF 50 kDa did not correlate (Table S1).
3.2 Neuroserpin and tPA levels in plasma and
CSF from individuals with DS and DSAD
The plasma levels of neuroserpin were similar between all groups
(Figure 2A, P> .05). In contrast, CSF neuroserpin levels were increased
in subjects with DS (both aDS and DSAD), compared to non-trisomic
controls (Figure 2B, P< .001, P< .05).
Plasma levels of the neuroserpin target, tPA, were reduced in aDS
and DSAD compared to non-trisomic controls (Figure 2C, P < .001
and P < .01). However, no such alteration was detectable in CSF from
the same individuals (Figure 2D, P > .05). We observed no correlation
between plasma and CSF levels of neuroserpin or tPA (Table S1).
F IGURE 1 Upregulation of proNGF (nerve growth factor) in
plasma and cerebrospinal fluid (CSF) from people with Down
syndrome (DS). A, The 27 kDa form of proNGF, measured byWestern
blotting, is upregulated in plasma fromAlzheimer’s disease
(AD)-asymptomatic people with Down syndrome (aDS) and in Down
syndromewith symptomatic AD (DSAD) compared to non-trisomic
controls, one-way analysis of variance (ANOVA), F= 5.03, P= .01 and
Bonferroni post hoc correction; *P< .05. B, ProNGF (27 kDa) is also
upregulated in CSF from people with aDS andDSAD compared to
non-trisomic controls, KruskalWallis test P= .0002H= 16.83 and
Dunn’s post hoc correction; **P< .01; ***P< .001. C, The 50 kDa form
of proNGF is upregulated in plasma from people with aDS andDSAD
compared to non-trisomic controls, one-way ANOVA, F= 5.62,
P= .006 and Bonferroni post hoc correction; *P< .05. D, 50 kDa
proNGF is upregulated in the CSF of people with aDS compared to
non-trisomic controls, and further upregulated in people with DSAD,
one-way ANOVA, F= 21.17, P< .0001 and Bonferroni post-hoc
correction; ***P< .001. Data are displayed in box andwhisker plots, in
which themedian is represented by the horizontal line and the
whiskers go from each quartile to theminimum ormaximum value.
HC, Healthy controls: n= 16, aDS: n= 14, DSAD: n= 22; IOD,
integrated optical density
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F IGURE 2 Dysregulation of neuroserpin and tissue plasminogen
activator (tPA) in plasma and cerebrospinal fluid (CSF) from people
with Down syndrome (DS). A, Neuroserpin levels were assessed by
Western blotting. No significant change in plasma neuroserpin levels
were observed between clinical groups, one-way analysis of variance
(ANOVA), P> .05. B, Neuroserpin levels were found upregulated in
CSF fromAD-asymptomatic people with Down syndrome (aDS) and
from people with Down syndrome and symptomatic Alzheimer’s
disease (DSAD) compared to non-trisomic controls, KruskalWallis test
P= .001H= 13.63 andDunn’s post hoc correction; *P< .05; **P< .01.
C, tPA levels were reduced in plasma from people with aDS andDSAD,
compared to non-trisomic controls, one-way ANOVA, F= 12.07,
P< .0001 and Bonferroni post hoc correction; *P< .05. D, No change
between clinical classifications in CSF levels of tPA, one-way ANOVA,
P> .05. tPA levels were determined by enzyme-linked immunosorbent
assay. Data are displayed in box andwhisker plots, in which themedian
is represented by the horizontal line and the whiskers go from each
quartile to theminimum ormaximum value. HC, Healthy controls:
n= 16, aDS: n= 14, DSAD: n= 22; IOD, integrated optical density
3.3 Analysis of metalloproteases in plasma and
CSF from individuals with aDS and DSAD
TheNGF-degrading proteinaseMMP-9was found unaltered in plasma
between the different groups (Figure 3A, P> .05). However, analysis of
CSF samples revealed increasedMMP-9 levels in theDSADgroup com-
pared to both the aDS group and the non-trisomic controls (Figure 3B,
F IGURE 3 Dysregulation of matrix metalloproteinases (MMP) 9,
3, and 1 in plasma and cerebrospinal fluid (CSF) from people with
Down syndrome (DS). A, No change between clinical classifications in
plasma levels ofMMP-9, KruskalWallis test, P> .05, Healthy controls
(HC): n= 16, AD-asymptomatic Down syndrome (aDS): n= 14, Down
syndromewith symptomatic Alzheimer’s disease (DSAD): n= 22. B,
CSFMMP-9 levels were elevated in people DSAD compared to aDS
and non-trisomic controls, one-way analysis of variance (ANOVA),
F= 5.90, P= .007 and Bonferroni post hoc correction; *P< .05,
**P< .01 HC: n= 13, DS: n= 10, DSAD: n= 12. C, Both DSAD and aDS
groups showed greater plasma levels ofMMP-3 compared to
non-trisomic controls, KruskalWallis test P= .003H= 11.83 and
Dunn’s post hoc correction; *P< .05; **P< .01, HC: n= 16, DS: n= 14,
DSAD: n= 22. D, CSFMMP-3was likewise elevated in people with
aDS andwith DSAD compared to non-trisomic controls, Kruskal
Wallis test P= .001H= 13.47 andDunn’s post hoc correction;
*P< .05; **P< .01, HC: n= 16, DS: n= 13, DSAD: n= 21. E,While no
significant post hoc differences in plasmaMMP-1 expression were
observed between clinical classifications, trends of P= .08 and P= .07
toward upregulations in the aDS andDSAD groups compared to
non-trisomic controls were observed P= .03, H= 6.85. F, MMP-1was
significantly upregulated in CSF from people with aDS compared to
healthy controls and DSAD, KruskalWallis test P= .0035H= 11.31
andDunn’s post hoc correction; *P< .05; ***P< .001, HC: n= 15, DS:
n= 14, DSAD: n= 20.Metalloprotease levels were determinedwith a
sensitive multiplex array fromMesoScale Discovery. Data are
displayed in box andwhisker plots, in which themedian is represented
by the horizontal line and the whiskers go from each quartile to
theminimum ormaximum value
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P< .01 and P< .05). CSF and plasma levels ofMMP-9 did not correlate
(Table S1).
MMP-3, which has been proposed to activate pro-MMP-947 and
which we have also recently shown to degrade mature NGF but not
its pro-form (Pentz et al.88), was equivalently increased in plasma from
people with aDS and DSAD (Figure 3C, P < .05 and P < .01). MMP-3
was also elevated in both aDS and DSAD groups compared to controls
in CSF samples (Figure 3D, P < .01). Plasma and CSF levels of MMP-3
significantly correlated (P< .001, r2= 0.41, Table S1).
MMP-1,which canbe activated byMMP-3,48 was unchanged across
clinical classifications, though there was a trend toward upregulations
in plasma in both the aDS and DSAD groups (Figure 3E, aDS vs HC:
P= .08; DSAD vs HC: P= .07). In paired CSF samples, MMP-1 was ele-
vated in the aDS group compared to both non-trisomic controls and to
people with DSAD (Figure 3F, P< .001, P< .05). Plasma and CSF levels
ofMMP-1 did not correlate (Table S1).
3.4 Specificity of NGF pathway markers to AD in
DS
The ability of eachmarker of theNGFmetabolic pathway to specifically
signal changes associated with symptomatic AD in DS was assessed
with the ROC curve analyses. Two candidates showed good and com-
parable performance: the 50 kDa form of proNGF measured in CSF
(Figure 4A, AUC = 0.86) and CSF MMP-9 (Figure 4B, AUC = 0.87).
These two markers showed better specificity for differentiating aDS
and DSAD than two of three core biomarkers of AD that were com-
pared for reference, including CSF 181-phospho-tau (p-tau, Figure 4C,
AUC = 0.85) and total tau (t-tau, Figure 4C; AUC = 0.75). The CSF
Aβ42/40 ratio performed slightly better than the proposed markers,
with an AUC = 0.88 (Figure 4C). All other NGF metabolism-related
markers had AUC values between 0.51 and 0.76 (Figure S2 in Supple-
mentary Files).
3.5 Associations between NGF
metabolism-related proteins and core biomarkers of
AD
Using robust regression (MM Estimation, following Croux et al.41), we
next assessed the relationship between NGF metabolism-related pro-
teins (which are not considered to be independent) and the established
core AD biomarkers measured in CSF: the Aβ42/40 ratio, p-tau, and
t-tau (see Tables 2 and 3). Adjusted r2 values are given. In addition,
we examined associations with each Aβ species individually and the
p-tau/Aβ42 ratio (see Tables 2 and 3). The two composites have both
been proposed to outperform their component individual measures as
biomarkers of AD.49–52
The expression of NGF metabolism-related markers in plasma was
typically uncorrelated to the three core AD CSF biomarkers, save
neuroserpin, which correlated weakly to Aβ40 (P = .02, r2= 0.07,
Table 2), Aβ42 (P= .01, r2= 0.09), and to the p-tau/Aβ42 ratio (P= .01,
F IGURE 4 Cerebrospinal fluid (CSF) matrix metalloproteinase
(MMP)-9 and proNGF (precursor of nerve growth factor) discriminate
effectively between Alzheimer’s disease (AD) symptomatic and
asymptomatic people with Down syndrome (DS). A, CSF levels of the
50 kDa proNGF form effectively identify people with Down syndrome
with symptomatic Alzheimer’s disease (DSAD) fromwithin the total
DS sample group, with an area under the receiver operator
characteristic (ROC) curve of 0.86. B, CSFMMP-9 levels effectively
identify people with DSAD fromwithin the total DS sample group,
with an area under the ROC curve of 0.87. C, ROC curves for the core
CSF biomarkers of AD demonstrate thatMMP-9 and proNGF (50 kDa)
measured in CSF outperformed CSF pTau-181 (AUC= 0.85) and total
tau (AUC= 0.75), while being outperformed by the Aβ42/40 ratio
(AUC= 0.88)
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TABLE 2 Associations among plasma levels of NGFmetabolism-related proteins, age, and core biomarkers of AD (individual components and
composites) measured in cerebrospinal fluid, given by r2 and P values as determined by the robustMMestimationmethod of Croux et al.41 (all
cases, n= 52)
Plasmamarker Age Aβ40 Aβ42 p-tau-181 t-tau Aβ42/40 p-tau/Aβ42


































































































Abbreviations: Aβ, amyloid beta; AD, Alzheimer’s disease; MMP, matrix metalloproteinase; NGF, nerve growth factor; p-tau, phosphorylated tau; tPA, tissue
plasminogen activator; t-tau, total tau.
r2= 0.07). The results of MM estimates for all associations between
plasma NGF–related proteins and core AD biomarkers are given in
Table 2.
In CSF, the 27 kDa form of proNGF correlated weakly to the
Aβ42/Aβ40 ratio (P= .04, r2= 0.07, Table 3), as well as p-tau (P= .008,
r2= 0.10) and t-tau levels (P= .03, r2= 0.10). Aweak correlation to the
p-tau/Aβ42 ratio was also observed (P = .008, r2= 0.10). In contrast,
the 50 kDa proNGF form correlated well to the CSF Aβ42/Aβ40 ratio
(P< .0001, r2=0.38) aswell as p-tau (P= .01, r2=0.26), t-tau (P< .005,
r2=0.31), and the p-tau/Aβ42 ratio (P= .02, r2=0.28). Aweak correla-
tionbetween50kDaproNGF inCSFandAβ42 levelswas alsoobserved
(P = .04, r2= 0.07). There were also significant correlations between
CSFneuroserpin and theAβ42/Aβ40 ratio (P= .01, r2=0.09), aswell as
p-tau (P = .04, r2= 0.05) t-tau (P = .04, r2= 0.07), and the p-tau/Aβ42
ratio (P = .01, r2= 0.06). Conversely, no significant correlations were
observed between tPA and core CSF biomarkers of AD. The results of
MM estimates for all associations between CSF NGF–related proteins
and core AD biomarkers are given in Table 3.
CSF MMP-9 only correlated to measures of tauopathy: p-tau
(P < .0001, r2= 0.22) and t-tau (P = .005, r2= 0.19), and better still
to the p-tau/ Aβ42 ratio (P < .0001, r2= 0.26). CSF MMP-3, in con-
trast, correlated well to the Aβ42/Aβ40 ratio (P = .002, r2= 0.21),
though yet stronger was the association between MMP-3 levels and
CSF Aβ40 alone (P< .001, r2= 0.44). CSFMMP-3 also correlation to t-
tau (P= .003, r2=0.34) and to the p-tau/ Aβ42 ratio (P= .05, r2=0.19),
though a strong positive association between CSF MMP-3 and p-tau
did not survive correction (P= .17, r2= 0.50). Last, CSFMMP-1 corre-
lated to individual measures of CSF Aβ42 (P = .02, r2= 0.33), but not
to Aβ42, to their ratio, or to any measures of tauopathy. The results of
MM estimates for all associations between CSF NGF–related proteins
and core AD biomarkers are given in Table 3.
3.6 Effects of sex on the plasma and CSF
expression of NGF metabolism-related proteins
Given that some of ourmarkers showed specificity to symptomatic AD
in DS (ie, proNGF 50 kDa andMMP-9) or efficacy as measurements of
pathological processes associated with AD, we investigated whether
sex influenced the expression of NGF pathway proteins, as this could
have implications for setting biomarker thresholds. We observed an
interaction between sex and clinical diagnosis in the expression of
CSF neuroserpin, with males displaying higher levels of neuroserpin
in the non-trisomic controls and DSAD groups, but with females
displaying higher levels in the aDS group (Figure 5A, two-way ANOVA,
Pinteraction < .05). MMP-9was differentially expressed by sex in plasma,
with males expressing higher levels across all clinical conditions
(Figure 5B, two-way ANOVA, Pmain effect sex < .01). Likewise, males
had consistently greater levels of MMP-3, both in plasma (Figure 5C,
two-wayANOVA, Pmain effect sex < .001) and in CSF (Figure 5D, two-way
ANOVA, Pmain effect sex < .05). No other main effects of sex or interac-
tions between sex and clinical diagnosis were observed for other NGF
pathwaymarkers (Figure S3 in Supplementary Files).
4 DISCUSSION
People born with DS inexorably develop AD neuropathology through
their lifetimes,1–3,53–57 with lifetime risk estimates now more than
90%.58 The primary cause of this vulnerability is attributed to the trip-
lication of chromosome 21, which encodes the amyloid precursor pro-
tein (APP) gene, from which Aβ peptides are produced,6,59–61 though
other triplicated genes in chromosome 21 are also known to con-
tribute to cognitive impairment and to influence the development of
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TABLE 3 Associations among CSF levels of NGFmetabolism-related proteins, age, and core biomarkers of AD (individual components and
composites) measured in CSF, given by r2 and p values for each association as determined by the robustMMestimationmethod of Croux et al.41
(all cases, n= 52)
CSFmarker Age Aβ40 Aβ42 p-tau-181 t-tau Aβ42/40 p-tau/Aβ42


































































































Abbreviations: Aβ, amyloid beta; AD, Alzheimer’s disease; CSF, cerebrospinal fluid; MMP, matrix metalloproteinase; NGF, nerve growth factor; p-tau, phos-
phorylated tau; tPA, tissue plasminogen activator; t-tau, total tau.
AD pathology in DS.62–65 The inexorable progression of AD pathology
in this population, generally unmixed with other age-related diseases,
makes it ideal for assessing the ability of biofluid proteins to reflect
pathological changes occurring in the brain and thereby to support
these alterations. Biomarkers of preclinical AD-associated processes
could be especially valuable, as this is the stage at which therapeutic
intervention is most likely to be viable.66
AD, both in DS and in the sporadic population, is associatedwith the
degeneration of basal forebrain cholinergic neurons.5,7–14 This phe-
nomenon contributes to cognitive decline in the early phases of the
disease67,68 and is associated with disruptions of the NGF metabolic
pathway,15–18 as basal forebrain cholinergic neurons depend on a con-
tinuous target-derived supply of NGF for themaintenance of a healthy
cholinergic phenotype.18,19,69–71
Initial studies on the expression of NGF metabolism-related pro-
teins in frontal, temporal, and parietal cortex had shown that adults
with DS and AD-dementia express higher levels of proNGF and neu-
roserpin protein, lower levels of tPA mRNA, and higher levels of
MMP-9 activity and mRNA (likely reflecting higher MMP-9 protein
expression),15 and indicating reduced maturation of proNGF to mNGF
and increased degradation of mNGF. Furthermore, these changes also
occur in sporadicAD, both at symptomatic stages andprior to theonset
of overt dementia, where they correlate to cognitive decline and brain
cholinergic dysfunction.25,26
The present results in matched body fluids from people with DS
indicate that brain NGF pathway alterations are reflected in plasma
and, more faithfully, in CSF, as plasma did not reveal the upregula-
tions in MMP-9 or neuroserpin seen in DS brains.15 The finding of
NGF metabolic changes in individuals asymptomatic for AD supports
an early dysregulation of NGF metabolism alongside AD pathology in
DS and the utility of the methods described here for monitoring these
changes in research and potentially clinical settings.
Both the 27 and 50 kDa forms of proNGF were increased in DS
plasma and CSF (irrespective of AD symptomatology) compared to
non-trisomic controls; however, the 50 kDa form was further elevated
in the DSAD group compared to aDS. While the 27 kDa proNGF band
represents the unmodified neuronal form of the NGF precursor,72–74
higher molecular weight forms have also been frequently reported,
including a 41 kDa form secreted by cortical cells20 and a 50 kDa gly-
cosylated form.42,75,76
It is unsurprising that CSF markers outperformed plasma markers
as signals of neuropathology. First, the CSF compartment is in direct
contact with the CNS. Second, brain-derived pools of molecules
unaltered in plasma, such as MMP-9 and neuroserpin, may simply
be too small compared to those derived from other sources, such as
macrophages and neutrophils.77,78 Importantly, the plasma results
confirm the dysregulation of NGF metabolism-related proteins that
had been reported previously in a different and independent DS popu-
lation from Sicily, Italy, which similarly demonstrated the upregulation
of proNGF, MMP-9, and MMP-3 in plasma samples, with no changes
to neuroserpin.16 Novel biomarkers are needed in DS, in both research
and clinical contexts, to track specific pathological events and thereby
enable AD precision medicine.79,80 In this respect, we investigated
whether NGF pathway biomarkers reflected processes specific to
symptomatic individuals withDS that distinguished them from the rest
of theDS population. ROC analysis revealed thatMMP-9 (AUC= 0.87)
and the 50 kDa formof proNGFmeasured in CSF (AUC= 0.86) outper-
formed classical CSF biomarkers of AD, including p-tau (AUC = 0.85)
and t-tau (0.75), but not the Aβ42/40 ratio (0.88). Thus, we propose
that our markers are reflecting changes that are associated with the
onset of symptomatic AD in DS. Furthermore, proNGF and MMP-9
measured in CSF could assist in the identification of AD-related NGF
dysmetabolism and cholinergic dysfunction in the DS population. This
claim could be further investigated in future studies using markers
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F IGURE 5 Sex influences the expression of certain nerve growth factor (NGF) metabolism-related proteins in plasma and cerebrospinal fluid
(CSF). A, Sex/group interaction in the expression of CSF neuroserpin (two-way analysis of variance, interaction P< .05). B, Main effect of sex in the
expression of plasmamatrix metalloproteinase (MMP)-9 with consistently higher levels in males. C, Main effect of sex in the expression of plasma
MMP-3 (P< .01) with consistently higher levels in males. D,Main effect of sex (P< .05) in the expression of CSFMMP-3with consistently higher
levels in males
of cholinergic dysfunction accessible in plasma or CSF, or preferably,
by basal forebrain volumetry with structural magnetic resonance
imaging79,80 or the positron emission tomography imaging of cholin-
ergic synapses.81,82 It is nonetheless worth noting that the direct
impact of NGF dysregulation on the cholinergic/cognitive phenotype
has been demonstrated experimentally in rodents18,19 and that NGF
dysmetabolism correlates to early cognitive decline and cholinergic
dysfunction in the human AD brain.26
While current biomarkers are able to effectively diagnose DSAD
from the wider DS population, proNGF could also play a role in sub-
typing and staging AD given that AD pathology and cholinergic degen-
eration differ in extent among neuroanatomical subtypes of AD.83 The
ability of proNGF to predict responses to cholinesterase inhibitor ther-
apy should also be investigated in this regard. Importantly, it is likely
that no single marker will prove to be an adequate diagnostic tool for
AD in isolation; proNGF and other relatedmarkersmay therefore have
utility as part of a larger diagnostic panel.
Significant sex-related dimorphisms have been observed in the inci-
dence and nature of AD, with important implications for diagnosis
and treatment.84 The present study further suggests that sex-specific
thresholds may also aid the clinical implementation of biomarkers.
We observed sex-related differences in MMP-9 (most significantly in
plasmabut also inCSF),whichwas oneof themarkers best able to iden-
tify individuals with AD dementia from DS at large, as well as MMP-3,
whichhasbeen shown to inform longitudinal riskofAD-associated cog-
nitive decline and has been reported to be increased in males in other
studies.16,85 Therefore, these results would indicate that any clinical
thresholds established for these markers should take the differential
expression of males and females into account. These differences may
also be relevant to the sex-related dimorphisms observed in the cholin-
ergic system and its dysfunction in AD.86
Whether theNGF biofluid signature reported inDS plasma andCSF
is unique toAD inDS remains to be thoroughly examined.Neuropatho-
logical studies have shown that proNGF (both forms), neuroserpin,
MMP-3, andMMP-9 (activity) are all increased,while tPA is unchanged
in the frontal cortex from people with sporadic AD or MCI, as well as
in cognitively normal people with elevated levels of brain amyloid.26
These results accordwell with the biomarker signature reported in the
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present study, and support its generalizability. These results are also
in accord with other accounts of increased proNGF in CSF from peo-
plewithAD,87 andwith the altered expression ofMMP-3, neuroserpin,
and plasminogen reported in CSF fromAD andMCI participants.40
Overall, the results of the present work arrive in a timely manner,
considering the new landscape of AD clinical trial initiatives being
launched for the DS population, in which biomarkers will play a crucial
role in AD staging and subtyping during recruitment as well as for
monitoring treatment response. Based on our results in this and other
studies we propose that proNGF and MMP-9, could play a significant
role in monitoring NGFmetabolism, cholinergic dysfunction, and early
cognitive decline in this population– a proposition awaiting further
confirmatory studies.
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